We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Agios (AGIO) Q1 Loss Wider than Expected; Sales Miss
Read MoreHide Full Article
Agios Pharmaceuticals, Inc. (AGIO - Free Report) is a development-stage biopharmaceutical company focused on the development of treatments for cancer and rare genetic metabolic disorders.
Agios received FDA approval for Idhifa (enasidenib) in August 2017 for the treatment of adult patients with relapsed or refractory AML (R/R AML) with an isocitrate dehydrogenase-2 (IDH2) mutation. It is the first FDA-approved therapy for the given indication.
The company has several interesting candidates in its pipeline. Interesting candidates in cancer pipeline includes IDH1 mutant inhibitor, AG-120 (ivosidenib) and a pan-IDH mutant inhibitor, AG-881. Ivosidenib is under priority review in the United States for treating patients with R/R AML with an IDH1 mutation. An approval for ivosidenib is expected in the third quarter of 2018. Additionally, the company anticipates a regulatory filing for the candidate in the EU during the fourth quarter of 2018 for the same indication.
Agios’ earnings performance so far has been mixed with the company beating expectations in two of the last four reported quarters and missing in the other two. Overall, the company has delivered an average negative surprise of 1.34%.
Currently, Agios has a Zacks Rank #3 (Hold), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Loss Wider: Agios posted wider-than-expected loss in the first quarter of 2018. Our consensus called for a loss of $1.60 per share, and the company reported a loss of $1.63. Reported loss was also wider than the year ago loss of $1.56.
Revenues Miss: Revenues in the reported quarter also came below expectations. Agios posted revenues of approximately $8.8 million, compared to our consensus estimate of $14 million. The revenues decreased 16.2% from year ago figure of $10.5 million.
Kay Stats: Research & development expenses were up 24.7% year over year to $78.2 million. General and administrative expenses increased 66.2% year over year to $24.5 million.
Share Price Impact: In-active in pre-market trading.
Check back later for our full write up on AGIO earnings report later!
Agios Pharmaceuticals, Inc. Price and EPS Surprise
It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
Image: Bigstock
Agios (AGIO) Q1 Loss Wider than Expected; Sales Miss
Agios Pharmaceuticals, Inc. (AGIO - Free Report) is a development-stage biopharmaceutical company focused on the development of treatments for cancer and rare genetic metabolic disorders.
Agios received FDA approval for Idhifa (enasidenib) in August 2017 for the treatment of adult patients with relapsed or refractory AML (R/R AML) with an isocitrate dehydrogenase-2 (IDH2) mutation. It is the first FDA-approved therapy for the given indication.
The company has several interesting candidates in its pipeline. Interesting candidates in cancer pipeline includes IDH1 mutant inhibitor, AG-120 (ivosidenib) and a pan-IDH mutant inhibitor, AG-881. Ivosidenib is under priority review in the United States for treating patients with R/R AML with an IDH1 mutation. An approval for ivosidenib is expected in the third quarter of 2018. Additionally, the company anticipates a regulatory filing for the candidate in the EU during the fourth quarter of 2018 for the same indication.
Agios’ earnings performance so far has been mixed with the company beating expectations in two of the last four reported quarters and missing in the other two. Overall, the company has delivered an average negative surprise of 1.34%.
Currently, Agios has a Zacks Rank #3 (Hold), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Loss Wider: Agios posted wider-than-expected loss in the first quarter of 2018. Our consensus called for a loss of $1.60 per share, and the company reported a loss of $1.63. Reported loss was also wider than the year ago loss of $1.56.
Revenues Miss: Revenues in the reported quarter also came below expectations. Agios posted revenues of approximately $8.8 million, compared to our consensus estimate of $14 million. The revenues decreased 16.2% from year ago figure of $10.5 million.
Kay Stats: Research & development expenses were up 24.7% year over year to $78.2 million. General and administrative expenses increased 66.2% year over year to $24.5 million.
Share Price Impact: In-active in pre-market trading.
Check back later for our full write up on AGIO earnings report later!
Agios Pharmaceuticals, Inc. Price and EPS Surprise
Agios Pharmaceuticals, Inc. Price and EPS Surprise | Agios Pharmaceuticals, Inc. Quote
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
See Them Free>>